Published in J Gen Virol on June 01, 1981
Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis (1974) 4.41
Measles outbreak in a fully immunized secondary-school population. N Engl J Med (1987) 2.75
Prevention of varicella by zoster immune globulin. N Engl J Med (1969) 2.57
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Partner's influence on patient preference for treatment in early prostate cancer. BJU Int (2003) 2.33
Role of cytoplasmic vacuoles in varicella-zoster virus glycoprotein trafficking and virion envelopment. J Virol (1988) 2.22
Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect Immun (1978) 2.15
Endocytosis and recycling of varicella-zoster virus Fc receptor glycoprotein gE: internalization mediated by a YXXL motif in the cytoplasmic tail. J Virol (1997) 2.14
Structural analysis of the varicella-zoster virus gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide moieties. J Virol (1985) 2.09
Enzyme-linked immunosorbent assay for susceptibility to varicella. J Infect Dis (1983) 2.03
Primary Epstein-Barr-virus infections in acute neurologic diseases. N Engl J Med (1975) 2.02
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J Virol (1994) 1.99
Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun (1983) 1.95
Egress of varicella-zoster virus from the melanoma cell: a tropism for the melanocyte. J Virol (1995) 1.89
Separation of infectious Varicella-Zoster virus from human embryonic lung fibroblasts. Virology (1967) 1.85
Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J Virol (1992) 1.81
The synthesis of glycoproteins in human melanoma cells infected with varicella-zoster virus. Virology (1980) 1.72
Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy. Virology (1995) 1.72
Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics (1981) 1.69
Cell-free varicella-zoster virus in cultured human melanoma cells. J Gen Virol (1979) 1.64
Complex formation facilitates endocytosis of the varicella-zoster virus gE:gI Fc receptor. J Virol (1998) 1.62
Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA (1983) 1.60
New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol (1986) 1.59
Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system. J Virol (1993) 1.58
Zoster immune globulin. A further assessment. N Engl J Med (1974) 1.57
Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J (1990) 1.53
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome. Virology (2001) 1.50
Varicella-zoster virus Fc receptor gE glycoprotein: serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms. J Virol (1997) 1.50
Site-directed mutagenesis of herpesvirus glycoprotein phosphorylation sites by recombination polymerase chain reaction. PCR Methods Appl (1992) 1.49
Varicella-zoster virus-specific gp140: a highly immunogenic and disulfide-linked structural glycoprotein. Virology (1984) 1.49
Multiple regulatory effects of varicella-zoster virus (VZV) gL on trafficking patterns and fusogenic properties of VZV gH. J Virol (1996) 1.49
Serine protein kinase associated with varicella-zoster virus ORF 47. Virology (1992) 1.48
Observations on the growth of varicella-zoster virus in human diploid cells. J Gen Virol (1973) 1.48
Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. J Clin Microbiol (1984) 1.47
Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster. J Infect Dis (1975) 1.47
Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex. Virology (1994) 1.46
Pyomyositis in an adolescent female athlete. J Pediatr Surg (1995) 1.43
Recent advances in varicella-zoster virus infection. Ann Intern Med (1999) 1.41
Chickenpox--examining our options. N Engl J Med (1991) 1.41
Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis (1979) 1.40
Lack of evidence of transmission of HIV-1 to family contacts of HIV-1 infected children. Clin Pediatr (Phila) (1998) 1.40
Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI. J Virol (1993) 1.40
Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology (2006) 1.39
Common expression of varicella-zoster viral glycoprotein antigens in vitro and in chickenpox and zoster vesicles. J Infect Dis (1983) 1.39
Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63. J Virol (2001) 1.37
Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology (1993) 1.36
Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology (1998) 1.35
Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression. J Virol (2001) 1.29
Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor. Virology (1990) 1.29
Risk factors for invasive group A streptococcal infections in children with varicella: a case-control study. Pediatr Infect Dis J (1996) 1.28
Zoster, reinfection or activation of latent virus? Observations on the antibody response. Am J Med (1970) 1.28
Specific immunoglobulin M enzyme-linked immunosorbent assay for confirming the diagnosis of measles. J Clin Microbiol (1986) 1.27
Interactions among structural proteins of varicella zoster virus. Arch Virol Suppl (2001) 1.27
Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII). Virology (1986) 1.23
Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics (1986) 1.19
Chaperone functions common to nonhomologous Epstein-Barr virus gL and Varicella-Zoster virus gL proteins. J Virol (1997) 1.18
Varicella zoster virus glycoprotein gpI is selectively phosphorylated by a virus-induced protein kinase. Proc Natl Acad Sci U S A (1986) 1.18
Bell's palsy and infectious mononucleosis. Lancet (1973) 1.17
Varicella-zoster virus infection of strain 2 guinea pigs. J Infect Dis (1985) 1.16
Prevention of varicella in high risk children: a collaborative study. Pediatrics (1972) 1.16
Passive immunization against varicella-zoster infections and other modes of therapy. J Infect Dis (1973) 1.15
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 1.15
Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J Virol (1999) 1.13
Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation. J Infect Dis (1984) 1.13
Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex). J Virol (1994) 1.13
Effect of early immunization on antibody response to reimmunization with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA). Pediatrics (1984) 1.12
Varicella-zoster infections in pregnancy. JAMA (1967) 1.08
Steroid therapy and varicella. J Pediatr (1972) 1.08
Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140). J Virol (1987) 1.07
Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. J Pediatr (1987) 1.03
Safe handling of vaccines. Pediatrics (1991) 1.03
Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins. J Virol (1985) 1.03
Unrecognized human immunodeficiency virus type 1 infection in a cohort of transfused neonates: a retrospective investigation. Pediatrics (1995) 1.03
Epstein-Barr virus and Guillain-Barré syndrome. Lancet (1972) 1.03
Herpesvirus antibody levels in the etiologic diagnosis of the acute retinal necrosis syndrome. Am J Ophthalmol (1992) 1.02
Cryopreservation of varicella-zoster virions without loss of structural integrity or infectivity. Intervirology (1981) 1.02
Immunoprecipitable polypeptides specified by varicella-zoster virus. Virology (1982) 1.01
Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics (1986) 1.00
Varicella-zoster virus p32/p36 complex is present in both the viral capsid and the nuclear matrix of the infected cell. J Virol (1986) 1.00
Children hospitalized for varicella: a prevaccine review. J Pediatr (1996) 0.99
Immunogenic glycoproteins of laboratory and vaccine strains of Varicella-Zoster virus. Infect Immun (1981) 0.99
Varicella vaccine--where are we? Pediatrics (1986) 0.99
Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis (1989) 0.98
Purification and molecular anatomy of the varicella-zoster virion. Biken J (1983) 0.96
Zoster in infancy: failure to maintain virus latency following intrauterine infection. J Pediatr (1981) 0.96
Case of infant botulism in Texas. Tex Med (1977) 0.96
Epitope mapping and tagging by recombination PCR mutagenesis. Biotechniques (1997) 0.95
Zoster in children with cancer: radioimmune precipitation profiles of sera before and after illness. J Infect Dis (1983) 0.95
Fetal and neonatal varicella-zoster infections. Semin Perinatol (1983) 0.95
Administration of live varicella vaccine to children wtih leukaemia. Lancet (1982) 0.95
Varicella-zoster viral glycoprotein envelopment: ultrastructural cytochemical localization. J Histochem Cytochem (1986) 0.95
Varicella-zoster virus glycoprotein gE: endocytosis and trafficking of the Fc receptor. J Infect Dis (1998) 0.93
Epidemiological standardization of a test for susceptibility to mumps. J Infect Dis (1984) 0.93
Primary Epstein-Barr virus infection in a renal transplant recipient. South Med J (1977) 0.92